Biotechnology

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

Shanghai is launching a massive tech festival in 2026. Is it a genuine gateway for global firms or a carefully curated showcase of China's industrial might?

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

Athletes are ditching complex supplement stacks for all-in-one EAA formulas. We explore the science and the industry shift fueling this minimalist movement.

Aethlon Medical is advancing a device to filter pathogens from the bloodstream, viewing it as a firewall for the body's internal communication network.

As Kewaunee Scientific preps its year-end report, all eyes are on whether its bold Nu Aire acquisition can translate revenue gains into long-term profit.

A new partnership between health tech pioneer Snke and biotech firm Precision NeuroMed aims to build a data-driven roadmap for treating neurological diseases.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

Polish biotech firm Urteste S.A. enrolls its first patient in a pivotal trial for a non-invasive pancreatic cancer test, a milestone in the global race for early diagnosis.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

NBA legend Shaquille O'Neal's campaign for Zepbound spotlights a silent health epidemic, but the drug's high cost and the ethics of celebrity ads loom large.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.